Tuesday, August 5, 2014

Juno Therapeutics Scores $134M More

Seattle-based biopharamceuticals developer Juno Therapeutics said this morning that it has raised $134M in a Series B funding. The funding came from ten public mutual funds and other healthcare-focused funds. Names of those exact investors was not disclosed. The funding brings the company's total raised north of $310M. Juno Therapeutics is developing immunotherapies for treating cancer. The company just raised a big, $176M funding in April. More information »